129 related articles for article (PubMed ID: 21114389)
1. Differences in clinical outcomes in patients with vancomycin-resistant enterococci according to linezolid susceptibility.
Scheetz MH; Knechtel SA; Postelnick MJ; Malczynski M; Qi C
Pharmacotherapy; 2010 Dec; 30(12):1221-8. PubMed ID: 21114389
[TBL] [Abstract][Full Text] [Related]
2. The clinical impact of linezolid susceptibility reporting in patients with vancomycin-resistant enterococci.
Scheetz MH; Qi C; Noskin GA; Warren JR; Postelnick MJ; Malczynski M; Huang J; Zembower TR
Diagn Microbiol Infect Dis; 2006 Dec; 56(4):407-13. PubMed ID: 16930924
[TBL] [Abstract][Full Text] [Related]
3. Gut overgrowth of vancomycin-resistant enterococci (VRE) results in linezolid-resistant mutation in a child with severe congenital neutropenia: a case report.
Verma N; Clarke RW; Bolton-Maggs PH; van Saene HK
J Pediatr Hematol Oncol; 2007 Aug; 29(8):557-60. PubMed ID: 17762497
[TBL] [Abstract][Full Text] [Related]
4. Treatment options for vancomycin-resistant enterococcal infections.
Linden PK
Drugs; 2002; 62(3):425-41. PubMed ID: 11827558
[TBL] [Abstract][Full Text] [Related]
5. Predictors and outcomes of linezolid-resistant vancomycin-resistant Enterococcus: a case-case-control study.
Hayakawa K; Marchaim D; Pogue JM; Ho K; Parveen S; Nanjireddy P; Sunkara B; Singla M; Jagadeesh KK; Moshos JA; Bommarito S; Mroue R; Farhat M; Obeid T; Chaudhry A; Vadlamudi G; Lephart PR; Martin ET; Rybak MJ; Kaye KS
Am J Infect Control; 2012 Dec; 40(10):e261-3. PubMed ID: 23199727
[TBL] [Abstract][Full Text] [Related]
6. First report of a linezolid- and vancomycin-resistant Enterococcus faecium strain in Korea.
Bae HG; Sung H; Kim MN; Lee EJ; Koo Lee S
Scand J Infect Dis; 2006; 38(5):383-6. PubMed ID: 16709544
[TBL] [Abstract][Full Text] [Related]
7. Risk factors and outcomes associated with vancomycin-resistant Enterococcus infections with reduced susceptibilities to linezolid.
Santayana EM; Grim SA; Janda WM; Layden JE; Lee TA; Clark NM
Diagn Microbiol Infect Dis; 2012 Sep; 74(1):39-42. PubMed ID: 22749382
[TBL] [Abstract][Full Text] [Related]
8. Comparison of outcomes from daptomycin or linezolid treatment for vancomycin-resistant enterococcal bloodstream infection: A retrospective, multicenter, cohort study.
Crank CW; Scheetz MH; Brielmaier B; Rose WE; Patel GP; Ritchie DJ; Segreti J
Clin Ther; 2010 Sep; 32(10):1713-9. PubMed ID: 21194593
[TBL] [Abstract][Full Text] [Related]
9. [In vitro activity of linezolid and dalbavancin against vancomycin-resistant enterococci].
Aktaş G; Bozdoğan B; Derbentli S
Mikrobiyol Bul; 2012 Jul; 46(3):359-65. PubMed ID: 22951648
[TBL] [Abstract][Full Text] [Related]
10. Impact of the more-potent antibiotics quinupristin-dalfopristin and linezolid on outcome measure of patients with vancomycin-resistant Enterococcus bacteremia.
Erlandson KM; Sun J; Iwen PC; Rupp ME
Clin Infect Dis; 2008 Jan; 46(1):30-6. PubMed ID: 18171210
[TBL] [Abstract][Full Text] [Related]
11. Varying linezolid susceptibility of vancomycin-resistant Enterococcus faecium isolates during therapy: a case report.
Swoboda S; Fritz S; Martignoni ME; Feldhues RA; Hoppe-Tichy T; Buchler MW; Geiss HK
J Antimicrob Chemother; 2005 Oct; 56(4):787-9. PubMed ID: 16143710
[TBL] [Abstract][Full Text] [Related]
12. Linezolid and quinupristin/dalfopristin resistance in vancomycin-resistant enterococci and methicillin-resistant Staphylococcus aureus prior to clinical use in Turkey.
Baysallar M; Kilic A; Aydogan H; Cilli F; Doganci L
Int J Antimicrob Agents; 2004 May; 23(5):510-2. PubMed ID: 15120733
[TBL] [Abstract][Full Text] [Related]
13. Vancomycin-resistant enterococcal bacteraemia: is daptomycin as effective as linezolid?
Mave V; Garcia-Diaz J; Islam T; Hasbun R
J Antimicrob Chemother; 2009 Jul; 64(1):175-80. PubMed ID: 19423543
[TBL] [Abstract][Full Text] [Related]
14. Nosocomial spread of linezolid-resistant, vancomycin-resistant Enterococcus faecium.
Herrero IA; Issa NC; Patel R
N Engl J Med; 2002 Mar; 346(11):867-9. PubMed ID: 11893808
[No Abstract] [Full Text] [Related]
15. Rapid emergence of resistance to linezolid during linezolid therapy of an Enterococcus faecium infection.
Seedat J; Zick G; Klare I; Konstabel C; Weiler N; Sahly H
Antimicrob Agents Chemother; 2006 Dec; 50(12):4217-9. PubMed ID: 16982791
[TBL] [Abstract][Full Text] [Related]
16. Determination of risk factors associated with isolation of linezolid-resistant strains of vancomycin-resistant Enterococcus.
Pogue JM; Paterson DL; Pasculle AW; Potoski BA
Infect Control Hosp Epidemiol; 2007 Dec; 28(12):1382-8. PubMed ID: 17994519
[TBL] [Abstract][Full Text] [Related]
17. Resistance to linezolid: characterization of mutations in rRNA and comparison of their occurrences in vancomycin-resistant enterococci.
Prystowsky J; Siddiqui F; Chosay J; Shinabarger DL; Millichap J; Peterson LR; Noskin GA
Antimicrob Agents Chemother; 2001 Jul; 45(7):2154-6. PubMed ID: 11408243
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study.
Florescu I; Beuran M; Dimov R; Razbadauskas A; Bochan M; Fichev G; Dukart G; Babinchak T; Cooper CA; Ellis-Grosse EJ; Dartois N; Gandjini H;
J Antimicrob Chemother; 2008 Sep; 62 Suppl 1():i17-28. PubMed ID: 18684703
[TBL] [Abstract][Full Text] [Related]
19. [Linezolid-resistant Enterococcus faecium: the first G2576T mutation in Turkey].
Afşar I; Barış I; Sener AG; Köksal V; Demirci M
Mikrobiyol Bul; 2012 Jul; 46(3):516-8. PubMed ID: 22951666
[TBL] [Abstract][Full Text] [Related]
20. Activity of oxazolidinone TR-700 against linezolid-susceptible and -resistant staphylococci and enterococci.
Livermore DM; Mushtaq S; Warner M; Woodford N
J Antimicrob Chemother; 2009 Apr; 63(4):713-5. PubMed ID: 19164418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
